Why is roche stock dropping. Roche shares last traded at $53. 18 hours ago · Roche's shares dropped more than 5% on Monday as the Swiss drugmaker failed to show that its promising breast cancer drug candidate giredestrant can help newly diagnosed patients. . The stock had previously closed at $55. stock is trading lower on Monday, in reaction to data from Roche Holdings AG’s phase 3 persevERA Breast Cancer study of giredestrant combined with palbociclib in 4 days ago · What's going on at Eli Lilly and Company (NYSE:LLY)? Read today's LLY news from trusted media outlets at MarketBeat. Get the latest financial news, headlines and analysis from CBS MoneyWatch. 1 day ago · Olema Pharmaceuticals Inc. 1 day ago · Roche’s next giredestrant readout is the pionERA trial, also expected in 2027. Breaking news and real-time stock market updates from Seeking Alpha. Roche stock tumbled Monday — giving way to steeper losses for Olema — after its oral breast cancer treatment failed in final-phase testing. hxk rkjr juy gqtcl nhtp ffev ucbwc olwoh odtbc mhcde